|
GSK’s linerixibat is currently under regulatory review in the US, Europe, and China, amongst other regions.
|
 |
|
Nabta Health is reimagining healthcare by putting women at the centre across the Gulf and Africa.
|
|
|
The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.
|
|
|
Ecnoglutide is distinguished by its selective activation of the cAMP signalling pathway, reducing β-arrestin recruitment.
|
|
|
According to GlobalData’s Pharma Clinical Trials Database, there are 80 planned and ongoing clinical trials (Phase II/III and III) sponsored by pharmaceutical companies for multiple myeloma.
|
|
|
Alnylam pens this deal with Tenaya as it looks to replicate the sales of its blockbuster ATTR-CM therapy, Amvuttra.
|
|
